Core C Clinical Trials Core: The function of Core C is to facilitate the translation of laboratory findings into the necessary clinical and correlative studies. This Clinical Trials Core provides the support and resources for activation, conduct and completion of the clinical trials or clinically-related aspects of each of the projects. This Core will provide the infrastructure so that concepts emanating from the projects can be evaluated for translational suitability, formulated into appropriate clinical protocols that will be carried out with the appropriate regulatory oversight, safety and collection of clinical data. This core is a necessary and vital component of the SARC Sarcoma SPORE and will streamline and standardize interaction with the clinical trial infrastructure of forty sarcoma clinical trials centers across the United States. The success of SARC is significantly based upon an outstanding record of accomplishment of designing, conducting and analyzing clinical trials in patients with sarcoma. SARC Clinical Trials Core leadership under the direction of Laurence Baker is experienced in facilitating multi-center research.
Currently there are limited programs that have the capabilities to provide the infrastructure for collaboration on clinical trial research for sarcoma. Because sarcoma is a relatively uncommon disease and that it occurs across the human like span, this clinical trial Core will provide the infrastructure to facilitate the conduct of clinical research to identify new beneficial treatment options for patients with sarcoma.
|Nakayama, Robert; Zhang, Yi-Xiang; Czaplinski, Jeffrey T et al. (2016) Preclinical activity of selinexor, an inhibitor of XPO1, in sarcoma. Oncotarget 7:16581-92|
|Goldstein, Seth D; Trucco, Matteo; Bautista Guzman, Wendy et al. (2016) A monoclonal antibody against the Wnt signaling inhibitor dickkopf-1 inhibits osteosarcoma metastasis in a preclinical model. Oncotarget 7:21114-23|
|Schaefer, Inga-Marie; Fletcher, Christopher Dm; Hornick, Jason L (2016) Loss of H3K27 trimethylation distinguishes malignant peripheral nerve sheath tumors from histologic mimics. Mod Pathol 29:4-13|
|MariÃ±o-EnrÃquez, AdriÃ¡n; BovÃ©e, Judith V M G (2016) Molecular Pathogenesis and Diagnostic, Prognostic and Predictive Molecular Markers in Sarcoma. Surg Pathol Clin 9:457-73|
|Tang, Qin; Moore, John C; Ignatius, Myron S et al. (2016) Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun 7:10358|
|Bobowski, Nina P; Baker, Laurence H (2016) The University of Michigan Sarcoma Survivorship Clinic: Preventing, Diagnosing, and Treating Chronic Illness for Improved Survival and Long-Term Health. J Adolesc Young Adult Oncol 5:211-4|
|Koehler, K; Liebner, D; Chen, J L (2016) TP53 mutational status is predictive of pazopanib response in advanced sarcomas. Ann Oncol 27:539-43|
|Bid, Hemant K; Phelps, Doris A; Xaio, Linlin et al. (2016) The Bromodomain BET Inhibitor JQ1 Suppresses Tumor Angiogenesis in Models of Childhood Sarcoma. Mol Cancer Ther 15:1018-28|
|Simon, Priscilla S; Bardhan, Kankana; Chen, May R et al. (2016) NF-ÎºB functions as a molecular link between tumor cells and Th1/Tc1 T cells in the tumor microenvironment to exert radiation-mediated tumor suppression. Oncotarget 7:23395-415|
|De Rienzo, Assunta; Archer, Michael A; Yeap, Beow Y et al. (2016) Gender-Specific Molecular and Clinical Features Underlie Malignant Pleural Mesothelioma. Cancer Res 76:319-28|
Showing the most recent 10 out of 86 publications